Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep

Jibriil P Ibrahim; Shadabul Haque; Robert J Bischof; Andrew K Whittaker; Michael R Whittaker; Lisa M Kaminskas

doi:10.3389/fphar.2022.880448

Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep

Front Pharmacol. 2022 Jun 2:13:880448. doi: 10.3389/fphar.2022.880448. eCollection 2022.

Authors

Jibriil P Ibrahim¹, Shadabul Haque², Robert J Bischof³, Andrew K Whittaker⁴, Michael R Whittaker², Lisa M Kaminskas¹

Affiliations

¹ School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia.
² Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
³ School of Science, Psychology and Sport, Federation University, Berwick, VIC, Australia.
⁴ Australian Institute for Bioengineering and Nanotechnology, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia.

Abstract

Enhancing the delivery of therapeutic agents to the lung lymph, including drugs, transfection agents, vaccine antigens and vectors, has the potential to significantly improve the treatment and prevention of a range of lung-related illnesses. One way in which lymphatic delivery can be optimized is via the use of nanomaterial-based carriers, such as liposomes. After inhaled delivery however, there is conflicting information in the literature regarding whether nanomaterials can sufficiently access the lung lymphatics to have a therapeutic benefit, in large part due to a lack of reliable quantitative pharmacokinetic data. The aim of this work was to quantitatively evaluate the pulmonary lymphatic pharmacokinetics of a model nanomaterial-based drug delivery system (HSPC liposomes) in caudal mediastinal lymph duct cannulated sheep after nebulized administration to the lungs. Liposomes were labelled with ³H-phosphatidylcholine to facilitate evaluation of pharmacokinetics and biodistribution in biological samples. While nanomaterials administered to the lungs may access the lymphatics via direct absorption from the airways or after initial uptake by alveolar macrophages, only 0.3 and 0.001% of the ³H-lipid dose was recovered in lung lymph fluid and lymph cell pellets (containing immune cells) respectively over 5 days. This suggests limited lymphatic access of liposomes, despite apparent pulmonary bioavailability of the ³H-lipid being approximately 17%, likely a result of absorption of liberated ³H-lipid after breakdown of the liposome in the presence of lung surfactant. Similarly, biodistribution of ³H in the mediastinal lymph node was insignificant after 5 days. These data suggest that liposomes, that are normally absorbed via the lymphatics after interstitial administration, do not access the lung lymphatics after inhaled administration. Alternate approaches to maximize the lung lymphatic delivery of drugs and other therapeutics need to be identified.

Keywords: Nanoparticles; inhalation; liposomes; lung lymph; mediastinal lymph; pharmacokinetics; sheep.